Cargando…

EZH2 in Myeloid Malignancies

Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silenci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinke, Jenny, Chase, Andrew, Cross, Nicholas C. P., Hochhaus, Andreas, Ernst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407223/ https://www.ncbi.nlm.nih.gov/pubmed/32650416 http://dx.doi.org/10.3390/cells9071639

Ejemplares similares

Mutational mechanisms of EZH2 inactivation in myeloid neoplasms
por: Chase, Andrew, et al.
Publicado: (2020)

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation
por: Hinze, Anna, et al.
Publicado: (2020)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

Myeloid Ezh2 Deficiency Limits Atherosclerosis Development
por: Neele, Annette E., et al.
Publicado: (2021)

Dual roles of EZH2 in acute myeloid leukemia
por: Skoda, Radek C., et al.
Publicado: (2019)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022)

Clinical Significance of EZH2 in Acute Myeloid Leukemia
por: Jiao, Weiyun, et al.
Publicado: (2022)

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
por: Li, Boheng, et al.
Publicado: (2019)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Retracted: Clinical Significance of EZH2 in Acute Myeloid Leukemia
por: Intelligence and Neuroscience, Computational
Publicado: (2023)

The role of EZH1 and EZH2 in development and cancer
por: Lee, Soo Hyun, et al.
Publicado: (2022)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
por: Zhang, Qi, et al.
Publicado: (2019)

Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies
por: Ernst, Philipp, et al.
Publicado: (2021)

Redistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes
por: Mortimer, Thomas, et al.
Publicado: (2019)

Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia
por: Hamed, Nahla A. M., et al.
Publicado: (2023)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

EZH2: An Accomplice of Gastric Cancer
por: Yu, Wuhan, et al.
Publicado: (2023)

Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
por: Schümann, Franziska Lea, et al.
Publicado: (2021)

EZH2 is a sensitive marker of malignancy in salivary gland tumors
por: Hajósi-Kalcakosz, Szofia, et al.
Publicado: (2015)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors
por: Neo, Wen Hao, et al.
Publicado: (2021)

Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia
por: Wang, Jingyi, et al.
Publicado: (2020)

Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution
por: Chen, Yulin, et al.
Publicado: (2023)

Regulation and Role of EZH2 in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2014)

The noncanonical role of EZH2 in cancer
por: Huang, Jinhua, et al.
Publicado: (2021)

The EHA Research Roadmap: Malignant Myeloid Diseases
por: Döhner, Hartmut, et al.
Publicado: (2021)

Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders
por: Midic, Danica, et al.
Publicado: (2020)

Post-translational modifications of EZH2 in cancer
por: Li, Zhongwei, et al.
Publicado: (2020)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

The molecular basis of myeloid malignancies
por: KITAMURA, Toshio, et al.
Publicado: (2014)

Survival with chronic myeloid leukaemia after failing milestones
por: Lauseker, Michael, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

The roles of EZH2 in cancer and its inhibitors
por: Liu, Yuankai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2c5vfikkv7sg3urdj91v8in4v8